- Development of small-molecule inhibitors targeting adipose triglyceride lipase.
Development of small-molecule inhibitors targeting adipose triglyceride lipase.
Nature chemical biology (2013-10-08)
Nicole Mayer, Martina Schweiger, Matthias Romauch, Gernot F Grabner, Thomas O Eichmann, Elisabeth Fuchs, Jakov Ivkovic, Christoph Heier, Irina Mrak, Achim Lass, Gerald Höfler, Christian Fledelius, Rudolf Zechner, Robert Zimmermann, Rolf Breinbauer
PMID24096302
ZUSAMMENFASSUNG
Adipose triglyceride lipase (ATGL) is rate limiting in the mobilization of fatty acids from cellular triglyceride stores. This central role in lipolysis marks ATGL as an interesting pharmacological target as deregulated fatty acid metabolism is closely linked to dyslipidemic and metabolic disorders. Here we report on the development and characterization of a small-molecule inhibitor of ATGL. Atglistatin is selective for ATGL and reduces fatty acid mobilization in vitro and in vivo.
MATERIALIEN
Produktnummer
Marke
Produktbeschreibung
Sigma-Aldrich
Esterase aus Schweineleber, ammonium sulfate suspension, ≥150 units/mg protein (biuret)
Sigma-Aldrich
Carboxylesterase 2 human, recombinant, expressed in baculovirus infected BTI insect cells
Sigma-Aldrich
Carboxylesterase 1 isoform b human, recombinant, expressed in baculovirus infected BTI insect cells
Sigma-Aldrich
Esterase aus Bacillus stearothermophilus, recombinant, expressed in E. coli, ≥4.0 U/mg
Sigma-Aldrich
Carboxylesterase 2 human, recombinant, expressed in mouse NSO cells, ≥95% (SDS-PAGE)
Sigma-Aldrich
Carboxylesterase 1 isoform c human, recombinant, expressed in baculovirus infected BTI insect cells
Sigma-Aldrich
Esteraseisoenzym-1 aus Schweineleber, rekombinant, recombinant, expressed in E. coli, ≥30.0 U/g